RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

REPLIGEN CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$176.43+1.01 (+0.58%)

Close on Oct 19, 2026

Market cap: $9.99B
P/E (TTM): 205.2
Dividend yield: –

REPLIGEN CORP income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2011 2011-03-31	FY 2010 2010-03-31
Revenue	738	634	632	802	671	366	270	194	141	105	84	64	68	27	21
Cost of Revenue	352	360	354	346	279	157	119	87	67	47	35	28	22	5.58	4.16
Gross Profit	386	275	278	456	391	210	151	108	74	57	48	36	46	22	17
Research & Development	54	43	43	44	34	20	19	16	8.67	7.36	5.74	5.61	7.34	13	14
Selling, General & Admin	291	263	219	216	184	120	96	66	52	31	25	17	13	8.02	7.07
Advertising Expenses	–	0.70	0.80	0.60	0.60	0.30	0.10	0.20	0.20	0.40	–	–	–	–	–
Total Costs & Expenses	683	670	585	577	503	296	234	168	127	89	70	53	45	28	27
Operating Income	55	-35	48	225	167	70	36	26	14	16	14	11	23	-0.37	-5.77
Interest Expense	22	21	2.50	1.16	11	11	9.29	6.71	6.44	3.77	0.03	0.05	0.05	0.03	0.00
Other Non-Operating Income	7.22	8.08	9.00	-5.53	-14	-11	-9.93	-4.55	-6.76	-4.28	-0.45	0.19	-0.11	–	–
Merger & Restructuring Charges	4.14	47	32	–	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	–	0	0	0	0	0	0	0	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	0	0	0	0	0	0	–	–
Gain (Loss) on Sale of Assets	–	-3.60	0	0	–	–	–	–	-0.06	-0.01	0.00	-0.04	0.00	-0.01	–
Pretax Income	62	-27	57	219	154	59	26	21	7.25	12	13	11	23	-0.04	-4.90
Income Tax Expense	13	-1.52	21	33	25	-0.71	4.74	4.82	-21	0.01	4.08	2.97	6.92	–	-0.83
Net Income	49	-26	36	186	128	60	21	17	28	12	9.35	8.17	16	-0.04	-4.06
EPS (Basic)(per share)	0.87	-0.46	0.64	3.35	2.33	1.14	0.44	0.38	0.74	0.35	0.28	0.25	0.51	0.00	-0.13
EPS (Diluted)(per share)	0.86	-0.46	0.63	3.24	2.24	1.11	0.44	0.37	0.72	0.34	0.28	0.25	0.50	0.00	-0.13
Shares Outstanding (Basic, Weighted)(shares)	0.06	0.06	0.06	0.06	0.06	0.05	48	44	38	0.03	33	32	32	31	31
Shares Outstanding (Diluted, Weighted)(shares)	0.06	0.06	0.06	0.06	0.06	0.05	49	45	39	0.03	34	33	32	31	31
EBITDA	134	35	116	276	206	97	57	42	25	21	18	15	26	1.30	-4.39

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 53.8%
Operating margin: 8.2%
Net margin: 5.3%
Return on equity, FY2025: 2.4%

Financial strength

Current ratio: 9.05
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 457.4%

Valuation

P/E ratio: 205.2
Price to sales: 12.73
Price to book: 4.73
Dividend yield: –